Koji Shido

TL;DR: A requirement for VEGFR1+ haematopoietic progenitor cells that express vascular endothelial growth factor receptor 1 (VEGFR1) home to tumour-specific pre-metastatic sites and form cellular clusters before the arrival of tumour cells is demonstrated.

TL;DR: It is reported that chemokine-mediated interactions of megakaryocyte progenitors with sinusoidal bone marrow endothelial cells (BMECs) promote thrombopoietin (TPO)-independent platelet production, and progenitor-active chemokines offer a new strategy to restore hematopoiesis in a clinical setting.

TL;DR: It is shown that inducible genetic ablation of vascular endothelial growth factor (VEGF)-A receptor-2 (VEGFR2) in the LSECs impairs the initial burst of hepatocyte proliferation and subsequent reconstitution of the hepatovascular mass by inhibiting upregulation of the endothelial-cell-specific transcription factor Id1, which suggests an instructive vascular niche in the early phases of physiological liver regeneration.

TL;DR: Hematopoietic cytokines, through graded deployment of SDF-1 from platelets, support mobilization and recruitment of CXCR4+VEGFR1+ hemangiocytes, whereas VEGFR1 is essential for their angiogenic competency for augmenting revascularization.

TL;DR: Angiogenic models are developed to demonstrate that EC-derived angiocrine growth factors support in vitro self-renewal and in vivo repopulation of authentic LT-HSCs, and establish an instructive vascular niche for clinical-scale expansion of LT- HSCs and a cellular platform to identify stem cell-active trophogens.